Consensus or Controversy, Issue 2: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Treatment of EGFR Mutation-Negative Metastatic Non-Small Cell Lung Cancer (NSCLC)

Consensus or Controversy, Issue 7: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Pancreatic Cancer

Consensus or Controversy, Issue 6: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Metastatic Colon Cancer

Consensus or Controversy, Issue 1: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Adjuvant Treatment of Localized Non-Small Cell Lung Cancer (NSCLC)

Consensus or Controversy, Issue 5: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Neoadjuvant/Adjuvant Treatment of Colorectal Cancer

Consensus or Controversy, Issue 3: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Metastatic Prostate Cancer

Consensus or Controversy, Issue 4: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Gastric Cancer

Faculty Comments on Anti-Angiogenesis in Gastric Cancer

In light of the AVAGAST trial data, do you expect that bevacizumab and newer-generation anti-angiogenic agents, such as ramucirumab, will play a significant role in the treatment of metastatic gastric cancer?

Syndicate content